# US 2021/0275440 A1 · Microbead compositions and methods for delivering an agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275440 A1
- Document ID: US20210275440A1
- Status: Published application
- Kind: A1
- Application number: 16/334,542
- Filed: 2017-09-27
- Published: 2021-09-09
- Earliest claimed: 2016-09-29
- Assignees: The University of Memphis Research Foundation
- Applicants: The University of Memphis Research Foundation
- Inventors: ANKITA MOHAPATRA; MICHAEL A. HARRIS; BASHIR I. MORSHED; JESSICA A. JENNINGS; JOEL BUMGARDNER; TOMOKO FUJIWARA; SANJAY R. MISHRA; DAVID A. LEVINE; GREGORY MCGRAW; WARREN O. HAGGARD
- Web page: https://patentgrep.com/patent/US20210275440A1

## CPC

- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1682: {Processes}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention provides microbeads comprising chitosan, a magnetic nanoparticle, and an agent, and methods for using such microbeads for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection or disease.

## Claims

### Claim 1

A microbead comprising cross-linked chitosan, a magnetic nanoparticle, and an agent.

### Claim 2 (depends on 1)

The microbead of claim 1, wherein the chitosan is cross-linked to a polymer.

### Claim 3 (depends on 3)

The microbead of claim 3, wherein the polymer is polyethylene dimethacrylate (PEGDMA).

### Claim 4 (depends on 1)

The microbead of claim 1, wherein the microbead comprises an effective amount of an agent selected from the group consisting of a polypeptide, polynucleotide or small compound.

### Claim 5 (depends on 1)

The microbead of claim 1, wherein the agent is an analgesic, angiogenic agent, antimicrobial, antibody, antifungal, anti-inflammatory, anti-thrombotic, chemotherapeutic, growth factor, hormone, or steroid agent.

### Claim 6 (depends on 1)

The microbead of claim 1, wherein the effective amount of the agent is sufficient to reduce the survival or proliferation of a fungal or bacterial cell.

### Claim 7 (depends on 1)

The microbead of claim 1, wherein the fungal cell is Candida albicans and/or the bacterial cell is Pseudomonas aeruginosa (lux) or Staphylococcus aureus.

### Claim 8 (depends on 1)

The microbead of claim 1, wherein the composition releases at least about 0.2-50 μg of an antimicrobial agent per hour.

### Claim 9 (depends on 1)

The microbead of claim 1, wherein the microbead is biodegradable over at least about one, two, three, four, or five days, or one, two, three, or four weeks.

### Claim 10

A method for producing a chitosan microbead, the method comprising:
(a) dissolving chitosan in an acidic solution;
(b) adding magnetic nanoparticles and an agent to the solution;
(c) providing a mixture of surfactant, oil, and a polymer; and
(d) adding the chitosan solution of step (a) to the oil and incubating until beads form.

### Claim 11 (depends on 1)

The method of claim 1, wherein step (a) further comprises incorporating an effective amount of one or more agents into the solution.

### Claim 12 (depends on 11)

A microbead generated according to the method of claim 11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for treating or preventing an infection in a subject at a site of trauma, the method comprising contacting the site with a chitosan microbead of any one of claims 1-9 and applying an external stimulus.

### Claim 14 (depends on 13)

The method of claim 13, wherein the trauma is selected from the group consisting of a fracture, open fracture, wound, complex wound, and surgical site.

### Claim 15 (depends on 13)

The method of claim 13, wherein the agent is selected from the group consisting of an analgesic, angiogenic agent, antimicrobial, antibody, antifungal, anti-inflammatory, anti-thrombotic, chemotherapeutic, growth factor, hormone, or steroid agent.

### Claim 16 (depends on 14)

The method of claim 14, wherein the antimicrobial agent is selected from the group consisting of antifungal, antibacterial, and antiviral agents.

### Claim 17 (depends on 14)

The method of claim 14, wherein the antimicrobial agents are amphotericin B, vancomycin, and/or amikacin.

### Claim 18 (depends on 14)

The method of claim 14, wherein the effective amount of the agent is sufficient to reduce the survival or proliferation of a bacterial cell.

### Claim 19 (depends on 14)

The method of claim 14, wherein the composition releases at least about 0.2-50 μg of an antimicrobial agent per hour.

### Claim 20 (depends on 14)

The method of claim 14, wherein the method reduces fungi or bacteria present at the site by at least about 20-100% at 72 hours after contact with the chitosan-microbead composition relative to an untreated control site.

### Claim 21 (depends on 13)

The method of claim 13, wherein the external stimulus is a magnetic field.

### Claim 22

A method for the local and temporally controlled delivery of an agent to a site, the method comprising contacting the site with a chitosan microbead comprising an agent and applying an external stimulus at a desired time point, thereby temporally controlling delivery of the agent to the site.

### Claim 23 (depends on 22)

The method of claim 22, wherein the agent is selected from the group consisting of an analgesic, angiogenic agent, antimicrobial, antibody, antifungal, anti-inflammatory, anti-thrombotic, chemotherapeutic, growth factor, hormone, or steroid agent.

### Claim 24 (depends on 22)

The method of claim 22, wherein the microbead releases about 2 μg-1000 mg of the agent in 1-72 hours.

### Claim 25 (depends on 22)

The method of claim 22, wherein the stimulus is a magnetic field.

### Claim 26 (depends on 22)

The method of claim 22, wherein the stimulus is applied for 30 minutes.

### Claim 27 (depends on 1)

A kit comprising a chitosan microbead of claim 1 for use in treating a trauma site or delivering an agent.

### Claim 28 (depends on 24)

The kit of claim 24, wherein the chitosan microbead comprises an agent selected from the group consisting of an analgesic, angiogenic agent, antimicrobial, antibody, antifungal, anti-inflammatory, anti-thrombotic, chemotherapeutic, growth factor, hormone, or steroid agent.
